Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
-
Published:2023-10-18
Issue:10
Volume:15
Page:2486
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Rodriguez-Vera Leyanis1ORCID, Yin Xuefen1ORCID, Almoslem Mohammed1, Romahn Karolin1, Cicali Brian1ORCID, Lukacova Viera2, Cristofoletti Rodrigo1, Schmidt Stephan1ORCID
Affiliation:
1. Center for Pharmacometrics and System Pharmacology at Lake Nona (Orlando), Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA 2. Simulations Plus, Lancaster, CA 93534, USA
Abstract
Regulatory agencies worldwide expect that clinical pharmacokinetic drug–drug interactions (DDIs) between an investigational new drug and other drugs should be conducted during drug development as part of an adequate assessment of the drug’s safety and efficacy. However, it is neither time nor cost efficient to test all possible DDI scenarios clinically. Phenytoin is classified by the Food and Drug Administration as a strong clinical index inducer of CYP3A4, and a moderate sensitive substrate of CYP2C9. A physiologically based pharmacokinetic (PBPK) platform model was developed using GastroPlus® to assess DDIs with phenytoin acting as the victim (CYP2C9, CYP2C19) or perpetrator (CYP3A4). Pharmacokinetic data were obtained from 15 different studies in healthy subjects. The PBPK model of phenytoin explains the contribution of CYP2C9 and CYP2C19 to the formation of 5-(4′-hydroxyphenyl)-5-phenylhydantoin. Furthermore, it accurately recapitulated phenytoin exposure after single and multiple intravenous and oral doses/formulations ranging from 248 to 900 mg, the dose-dependent nonlinearity and the magnitude of the effect of food on phenytoin pharmacokinetics. Once developed and verified, the model was used to characterize and predict phenytoin DDIs with fluconazole, omeprazole and itraconazole, i.e., simulated/observed DDI AUC ratio ranging from 0.89 to 1.25. This study supports the utility of the PBPK approach in informing drug development.
Subject
Pharmaceutical Science
Reference80 articles.
1. Drug-Drug Interactions among Elderly Patients Hospitalized for Drug Toxicity;Juurlink;JAMA,2003 2. Drug-Drug Interactions Related to Hospital Admissions in Older Adults: A Prospective Study of 1000 Patients;Doucet;J. Am. Geriatr. Soc.,1996 3. Drug-Drug Interaction Studies: Regulatory Guidance and an Industry Perspective;Prueksaritanont;AAPS J.,2013 4. Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective;Shebley;Clin. Pharmacol. Ther.,2018 5. Talati, R., Scholle, J.M., Phung, O.J., Baker, W.L., Baker, E.L., Ashaye, A., Kluger, J., Quercia, R., Mather, J., and Giovenale, S. (2011). Effectiveness and Safety of Antiepileptic Medications in Patients with Epilepsy, Agency for Healthcare Research and Quality (US). [40th ed.].
|
|